Efficacy and Safety of Trifluridine/Tipiracil Combined With Fufuquitinib for Third-line Treatment of mCRC

Sponsor
First Affiliated Hospital of Wenzhou Medical University
Study ID
NCT06485713
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Drug Therapy
  • Metastatic Colorectal Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • trifluridine/tipiracil combined with fufuquitinib — DRUG
    trifluridine/tipiracil combined with fufuquitinib
  • fufuquitinib — DRUG
    fufuquitinib
  • Trifluridine/tipiracil — DRUG
    Trifluridine/tipiracil

Study Details

To evaluate the efficacy and safety of trifluridine/tipiracil combined with fufuquitinib versus trifluridine/tipiracil and fufuquitinib in patients with unresectable metastatic colorectal cancer.

Key Dates

First listed
Jul 3, 2024
Start date
Mar 1, 2024
Status verified
Jul 2024
Primary completion
Jun 1, 2026
Completion
Jun 1, 2026

Study Design

Enrollment
200 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental group
    trifluridine/tipiracil combined with fufuquitinib
  • Active Comparator: Control Group 1
    Fufuquitinib
  • Active Comparator: Control Group 2
    Trifluridine/tipiracil

Primary Outcome Measure

Progression-free survival [ Time Frame: up to 24 weeks ]

Related Studies